Novo Nordisk enters into research collaboration with Lumen Bioscience

The research-based collaboration will evaluate Lumen Bioscience's technology platform with the aim of creating oral medicines for obesity and other metabolic diseases.

Photo: Stine Tidsvilde

Novo Nordisk and Lumen Bioscience have entered into a research collaboration, according to a press release from the US company.

According to their agreement, the companies will evaluate Lumen's technology platform and explore new strategies for creating oral biologics for treating obesity and other cardiometabolic diseases.

Read the whole article

Get 14 days free access.
No credit card required.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Pfizer upgrades guidance for sales of covid-19 vaccine

The US pharmaceutical company Pfizer now predicts sales of its coronavirus vaccines will total USD 33.5bn this year. The previous estimate was UDS 26bn. Meanwhile, the company has revealed the guidance for its annual revenue.

Further reading

Trial banner

Latest news

See all jobs